For example, the Keynote-024 and Keynote-189 trials demonstrated improved progression-free and overall survival in NSCLC patients with a PD-L1 tumor proportion score (TPS) above 50% treated with Pembrolizumab [13,14]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.